Medreich PLC

Mebaverine hydrochloride 135mg Film-coated Tablets

<table>
<thead>
<tr>
<th>Batch Number</th>
<th>Expiry Date</th>
<th>Pack Size</th>
<th>First Distributed</th>
</tr>
</thead>
<tbody>
<tr>
<td>B11539</td>
<td>11/2024</td>
<td>100 tablets</td>
<td>25 August 2022</td>
</tr>
</tbody>
</table>

Active Pharmaceutical Ingredient: Mebeverine hydrochloride

Brief description of the problem
Medreich Plc UK is recalling the above batch as a precautionary measure due to out of specification results for tablet dissolution during routine product release testing.

Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients
- No further action is required by patients as this is a Pharmacy and Wholesaler level recall.
- Patients should continue to take medicines from this batch as prescribed by your healthcare professional.
- The Marketing Authorisation Holder has not received any reports of adverse reactions related to this issue. However, patients who experience adverse reactions or insufficient control of symptoms should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information
For more information or supply enquiries, please contact Medreich PLC at cs_team@medreich.co.uk or by phone at 0208 831 1580, 0208 831 1511 or 0208 831 1509

For medical information queries, please contact pharmacovigilance@medreich.com

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk